Peginterferon beta-1a - Ambrx/Merck Serono

Drug Profile

Peginterferon beta-1a - Ambrx/Merck Serono

Alternative Names: ARX 424

Latest Information Update: 09 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambrx
  • Developer Ambrx; Merck Serono
  • Class Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 09 Jan 2014 No development reported - Phase-I for Multiple sclerosis in USA (Parenteral)
  • 23 Feb 2011 Phase-I clinical trials in Multiple sclerosis in USA (Parenteral)
  • 26 Feb 2009 Preclinical trials in Multiple sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top